While large parts of the molecular profile of SCLC remain untargetable, neuroendocrine characteristics with notable expression of type 2 somatostatin receptors (SSTR2) in a relevant fraction of patients 7 suggest a potential for SSTR2-directed theranostics 8. Here, SSTR2 is linked to small cell lung carcinoma.